NCT02595320: Capecitabine in Metastatic Breast and GI Cancers

NCT02595320
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic brain or CNS metastases, or leptomeningeal disease
https://ClinicalTrials.gov/show/NCT02595320

Comments are closed.

Up ↑